Key result
SGLT2 inhibitors improve prognosis and reduce restenosis after PCI.
Why the study?
Restenosis remains the primary limiting factor for the long-term success of PCI, prompting evaluation of the clinical studies and mechanisms of SGLT2 inhibitors in its prevention.
Does SGLT2 inhibitor improve prognosis and prevent in-stent restenosis in patients with coronary heart disease undergoing PCI?
Does SGLT2 inhibitor improve prognosis and prevent in-stent restenosis in patients with coronary heart disease undergoing PCI?
This review highlights that SGLT2 inhibitors can improve clinical prognosis and prevent in-stent restenosis in patients after PCI, extending their cardiovascular benefits beyond heart failure and diabetes.
Answers are grounded in this paper and cite their sources.
May support SGLT2 inhibitor evaluation post-PCI; hypothesis-generating and requires randomized confirmation before practice change.
Coronary heart disease is a narrowing or obstruction of the vascular cavity caused by atherosclerosis of the coronary arteries, which leads to myocardial ischemia and hypoxia. At present, percutaneous coronary intervention (PCI) is an effective treatment for coronary atherosclerotic heart disease. Restenosis is the main limiting factor of the long-term success of PCI, and it is also a difficult problem in the field of intervention. Sodium-glucose cotransporter 2 (SGLT2) inhibitor is a new oral glucose-lowering agent used in the treatment of diabetes in recent years. Recent studies have shown that SGLT2 inhibitors can effectively improve the prognosis of patients after PCI and reduce the occurrence of restenosis. This review provides an overview of the clinical studies and mechanisms of SGLT2 inhibitors in the prevention of restenosis, providing a new option for improving the clinical prognosis of patients after PCI.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) conducted a review in Coronary heart disease post-PCI. SGLT2 inhibitors was evaluated on Prognosis and in-stent restenosis. SGLT2 inhibitors can effectively improve the prognosis of patients after percutaneous coronary intervention and reduce the occurrence of restenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: